Table 8 Summary of studies that examined the safety of treatment interventions for people with diabetes
Study | Design | Subjects | Infection | Organism | Intervention | Assessment (week) |
|---|---|---|---|---|---|---|
Gupta [42] | RCT | Itraconazole N = 35 Sex = 16 M; 19 F Age = 57.77 (2.3) yr Terbinafine N = 35 Sex = 18 M; 17 F Age = 63.65 (1.9) yr | DLSO | Dermatophyte | Ciclopirox 8% Ciclopirox 8% nail lacquer applied to nail and 5 mm surrounding skin. Daily application over the previous coat, removed after 7 days using isopropyl alcohol. Nails trimmed and debrided at each scheduled visit (8 weeks) | 48 |
Brenner [43] | Case series | N = 49†Sex = 36 M; 13 F Age = 63.8 (12.0) yr Duration of diabetes = 8.4 (7.4) yr Duration of infection = 10.8 (15.3) yr | DSO††| Not reported†| Terbinafine 250 mg terbinafine daily 12 weeks | 48 |
Farkas [46] | Case series | N = 89 Sex = 47 M; 42 F Age = 55.7 (11.7) yr Duration of diabetes = 10.2 (7.7) Duration of infection = 5.4 (6.0) | DSO | Dermatophyte (67.4%); moulds (5.6%); yeast (4.5%) | Itraconazole pulse therapy 200 mg of oral itraconazole taken twice a day for the first week of three consecutive months Terbinafine 250 mg of oral terbinafine once daily for 12 weeks. | 48 |
Sadighha [41] | Case series | N = 13 Sex = NR Age = NR | DSO††| Dermatophyte†| Pulse itraconazole therapy 200 mg of oral itraconazole taken twice a day for the first week of four consecutive months | 26 |